reviewed april 2026|next review october 2026|88 physicians psi has verified|1421 published studies
Noopept (GVS-111)
Noopept (GVS-111) is a synthetic dipeptide derivative approved in Russia as a prescription nootropic, designed as a prodrug of the naturally occurring (the body's own) neuropeptide cycloprolylglycine, with Russian clinical data for cognitive disorders but no Western-standard randomized controlled trials.
Evidence landscape: 1421 published studies
1,421 published items. 4 human studies and 137 animal studies.
- 4 Human
- 137 Animal
- 59 Reviews
- 1221 Other research
Not FDA-approved. Approved as a prescription nootropic in Russia since 2006. Not approved by any Western regulatory authority.
Available by prescription in Russia. Sold as a supplement or research compound in other markets. Widely available online from peptide and nootropic suppliers.
Synthetic dipeptide-derived nootropic. Prodrug of cycloprolylglycine, a naturally occurring (the body's own) neuropeptide. Modulates AMPA and NMDA glutamate receptors and increases BDNF/NGF expression. Oral bioavailability is demonstrated, which is unusual for peptide-derived compounds.
PSI Assessment
One of the most widely discussed nootropic compounds in online biohacking communities, noopept (GVS-111) is approved in Russia as a prescription nootropic but has generated claims of cognitive enhancement that far outrun the published evidence. The compound is a synthetic dipeptide derivative of the naturally occurring (the body's own) neuropeptide cycloprolylglycine, designed as a prodrug that releases cycloprolylglycine after oral absorption. Russian clinical studies report cognitive improvements in patients with mild cognitive disorders. No Western-standard randomized controlled trials have been conducted, and the claims of '1000x more potent than piracetam' that circulate online refer to dosing equivalency, not pharmacological superiority.
Approved in Russia as a prescription nootropic. The '1000x more potent than piracetam' claim refers to dosing, not pharmacological superiority. No Western-standard RCTs.
The mechanism involves modulation of glutamate signaling through AMPA and NMDA receptors. As a prodrug, noopept is converted to cycloprolylglycine after oral absorption, which then modulates excitatory neurotransmission. It also increases BDNF and NGF expression in the hippocampus and cerebral cortex, which may contribute to the neuroprotective and memory-enhancing effects observed in animal models. Oral bioavailability is demonstrated, which is unusual for a peptide-derived compound.
What the evidence supports
Noopept modulates AMPA and NMDA glutamate receptor signaling and increases BDNF and NGF expression in animal models. Russian clinical studies report cognitive improvements in patients with mild cognitive disorders. Approved as a prescription nootropic in Russia since 2006. The prodrug conversion to cycloprolylglycine is pharmacologically characterized. Oral bioavailability is demonstrated.
What is not yet established
Whether noopept produces cognitive enhancement in healthy adults (Russian trials studied patients with existing cognitive impairment). No Western-standard randomized controlled trials have been conducted. Whether the online claims of dramatic nootropic effects reflect the published evidence. Long-term safety with chronic use.
Research Evidence
The findings below cover the Russian clinical data, the animal and laboratory mechanism, and the key gaps in Western validation.
Evidence by condition
Evidence dimensions across noopept research areas. Cognitive enhancement has Russian clinical data for impaired populations but no Western RCTs. Neuroprotection has consistent animal data. Anxiety research is at early animal study stage.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Cognitive Enhancement | ||||
| Neuroprotection | ||||
| Anxiety | ||||
| Memory |
Russian clinical studies report cognitive improvements in patients with mild cognitive disorders following cerebrovascular disease. Noopept has been approved as a prescription nootropic in Russia since 2006 based on this clinical data.
The clinical evidence comes from Russian institutions. Study designs do not consistently meet Western randomized controlled trial standards. The patient population studied had existing cognitive impairment, not healthy cognition.
Animal studies consistently demonstrate BDNF and NGF upregulation in hippocampus and cerebral cortex following noopept administration. These neurotrophic factors are critical for neuronal survival and synaptic plasticity.
The neurotrophic mechanism is well-characterized in animal models and provides a plausible basis for the cognitive effects. Whether this translates to meaningful cognitive enhancement in healthy humans is not established.
The '1000x more potent than piracetam' claim that circulates in online communities refers to the effective dose by weight, not to pharmacological superiority. Noopept is active at much lower doses (10-30 mg vs piracetam's 1200-4800 mg), but lower dosing does not equate to greater cognitive benefit.
This distinction is critical for informed evaluation. The potency comparison is frequently misrepresented as a claim of 1000x greater cognitive enhancement.
4 Human|137 Animal|59 Reviews
View all 1421 indexed studiesHow Noopept (GVS-111) Works
Noopept (GVS-111) is a synthetic dipeptide derivative, meaning it is a small molecule designed from a two-amino-acid building block. It was developed at the Russian Academy of Sciences as a prodrug, a compound designed to convert into an active molecule after absorption. Once taken orally, noopept is converted to cycloprolylglycine, a naturally occurring (the body's own) neuropeptide that modulates brain signaling.
Noopept works by increasing the activity of two brain chemicals that are critical for learning and memory: glutamate (the brain's main excitatory signal) and acetylcholine (the neurotransmitter most associated with memory formation). It also increases levels of BDNF and NGF, proteins that help brain cells grow and survive.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) is metabolized to cycloprolylglycine, a naturally occurring neuropeptide. It modulates AMPA and NMDA glutamate receptor transmission, enhancing long-term potentiation (LTP). It increases BDNF and NGF expression in the hippocampus and cerebral cortex. The compound also modulates acetylcholine transmission and demonstrates antioxidant and anti-inflammatory properties in neural tissue. Oral bioavailability is approximately 10%, which is high for a peptide-derived compound.
What is Noopept (GVS-111) being studied for?
Researchers are studying Noopept (GVS-111) across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Noopept (GVS-111) overall. This means a compound can have human studies for one condition but only animal data for another.
Cognitive Enhancement
·Human TrialsRussian clinical studies report improved learning, memory, and attention in patients with cognitive impairment following cerebrovascular disease. Approved as a prescription nootropic in Russia.
Limitations: Whether noopept enhances cognition in healthy adults is not established by controlled trials. Russian clinical data has not been independently replicated in Western institutions.
Neuroprotection
·Animal StudiesAnimal data shows noopept protects neurons from oxidative stress, excitotoxicity, and amyloid-beta toxicity. The BDNF and NGF upregulation provides a plausible neuroprotective mechanism.
Limitations: No human neuroprotection studies. Whether the animal neuroprotection translates to Alzheimer's prevention or any human neurodegenerative condition is unknown.
Anxiety
·Animal StudiesSome animal data and community reports suggest anxiolytic effects, possibly through glutamate modulation.
Limitations: No human anxiety studies. Anxiolytic effects are primarily anecdotal and extrapolated from animal models.
Memory
·Animal StudiesAnimal studies show improved memory consolidation and recall. Russian clinical data supports memory improvement in cognitively impaired populations.
Limitations: The memory improvement data in humans is limited to patients with existing cognitive impairment. Extrapolation to healthy memory enhancement is not supported.
Safety and Regulatory Status
FDA Status: Not FDA-approved. Approved as a prescription nootropic in Russia since 2006. Not recognized as a therapeutic agent by any Western regulatory authority.
Availability: Prescription medication in Russia. Sold as a supplement or research compound in other markets. Widely available from online peptide and nootropic suppliers without prescription.
Class context: Clinical use in Russia reports a favorable safety profile. Common side effects are mild and include headache, irritability, and sleep disturbance at higher doses. Long-term safety data from Western-standard monitoring is not available.
Noopept has been used clinically in Russia with a favorable reported safety profile. The most common side effects at therapeutic doses are mild headache and occasional sleep disturbance. Long-term safety with chronic use (the typical pattern in nootropic communities) has not been formally studied in any regulatory framework.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a Noopept (GVS-111) discussion.
Comparison and Related Research
Noopept is most often compared with other nootropic compounds, particularly those with Russian regulatory approval. The comparisons below outline how each differs.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Clinical study evaluating noopept in patients with mild cognitive impairment following stroke. Treatment was associated with improvements in cognitive function scores, providing human evidence that the preclinical neuroprotective and nootropic effects observed in animal models may translate to clinical benefit.Amelin AV et al., 2011 in Zh Nevrol Psikhiatr Im S S Korsakova. View on PubMed
- 2.Identified cyclo-L-prolylglycine as the primary active metabolite of noopept (GVS-111) in the brain. This metabolite closely resembles an endogenous neuropeptide, suggesting that noopept may work by mimicking a naturally occurring brain signaling molecule involved in memory and learning processes.Gudasheva TA et al., 1997 in Eur J Drug Metab Pharmacokinet. View on PubMed
- 3.Demonstrated neuroprotective effects of noopept in a cellular model relevant to Alzheimer's disease. The compound reduced programmed cell death and decreased abnormal tau protein phosphorylation, two key pathological processes in neurodegeneration. These findings expanded the mechanistic understanding beyond earlier behavioral studies.Ostrovskaya RU et al., 2014 in J Biomed Sci. View on PubMed
- 4.Showed that noopept increases expression of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) in the hippocampus, a brain region central to memory formation. Both NGF and BDNF support neuron survival and growth, providing a molecular mechanism for the cognitive-enhancing effects observed in behavioral studies.Ostrovskaya RU et al., 2008 in Bull Exp Biol Med. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.